Wednesday, 14 Nov 2018

You are here

Adherence to Gout Therapies Painfully Low

There are numerous, highly effective urate-lowering therapies (ULT) to treat and prevent gout attacks, yet gout remains the most common undertreated and poorly treated form of arthritis.  While some of this responsibility lies with healthcare providers, patient factors may color the outcomes.

A retrospective study of the large UK Clinical Practice Research Datalink (1987–2014) sought to assess patient medication compliance in gout and found that adherence to allopurinol in gout is poor, especially among females and younger patients and those with fewer comorbidities. 

They examined newly diagnosed gout patients, ⩾40 years and starting allopurinol (n = 48 280). Non-persistence was measured as amedication gap of ⩾90 days after 1 and 5 years. Non-adherence identified patients whose complied with treatment <80% over the observation period. 

From year 1 to year 5, non-persistence increased from 38.5% to 56.9% after allopurinol initiation. After a first gap in therapy, 43.3% restarted allopurinol therapy within 1 year. Yet again only 52.3% persisted for 1 year.

Non-persistence and non-adherence were higher in females, current smokers.  Persistence and adherence were higher in older and overweight gout patients, those on anti-hypertensives or colchicine and those with comorbidities (dementia, diabetes or dyslipidemia). 

Another metanalysis of 24 studies similarly showed that ULT adherence was less than 48% and  that non-persistence ranged from 54% to 87%. In some of these studies, adherence positively correlated with older age, more comorbidities, and the presence of diabetes or hypertension. (Citation source: http://bit.ly/2wtjN1f)

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Treat-to-Target Strategy Cuts Mortality in Gout Patients

More intense treatment of gout with a treat-to-target strategy can reduce patients' risk for death, a Spanish researcher told a press conference Monday at the American College of Rheumatology annual meeting here.

TRIPLE Trial Results

Pegloticase has become an excellent option for management of patients with chronic refractory gout, although treatment may be limited by the development of anti-drug antibodies that lead to loss of serum urate (sUA) lowering effect.

Gout and the Social Determinants of Health

During a fascinating gout session on October 21, Hyon Choi presented an important paper (abstract 874) which used data from the Health Professionals Follow-up Study to try to understand the rapid increase in the incidence of gout in recent decades.

Nurse Led Gout Management Highly Effective

UK researchers have shown that nurse-led gout management, using a treat-to-target urate-lowering strategy, is efficacious and cost-effective compared with usual physicain care. The results are published in the recent Lancet edition.

Worldwide, gout management is suboptimal. In the UK only 40% of gout patients receive urate-lowering therapy, and fewer ever achieve a target serum urate (< 6mg/d) concentration.

It's the Genes, Not the Diet that Raises Urate

Researchers from New Zealand find that in contrast with genetic contributions, diet explains very little variation in serum urate levels in the general population.